DOTATATE acetate
Based on 4 publication(s) in Google Scholar
DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT). DOTATATE (acetate) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.95%
- No. CAS: 177943-89-4
- Fòrmula: C65H90N14O19S2.xC2H4O2
-
Almacenamiento:
Sealed storage, away from moisture and light, under nitrogen.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) DOTATATE acetate
More
Customer Validation & Images
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
Ver todos los productos específicos de isoformas Radionuclide-Drug Conjugates (RDCs)
More
Actividad biológica
|
RDC Peptide |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 177943-89-4
-
Appearance Solid
-
Fòrmula C65H90N14O19S2.xC2H4O2
-
Color White to off-white
-
Synonyms
Oxodotreotide acetate
-
Sequence
{DOTA}-{d-Phe}-Cys-Tyr-{d-Trp}-Lys-Thr-Cys-Thr (Disulfide bridge:Cys2-Cys7)
-
Sequence Shortening
{DOTA}-{d-Phe}-CY-{d-Trp}-KTCT (Disulfide bridge:Cys2-Cys7)
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Sealed storage, away from moisture and light, under nitrogen
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
J Nucl Med
The Emission of Internal Conversion Electrons Rather Than Auger Electrons Increased the Nucleus-Absorbed Dose for 161Tb Compared with 177Lu with a Higher Dose Response for [161Tb]Tb-DOTA-LM3 Than for [161Tb]Tb-DOTATATE. [Abstract]2024 Oct 1;65(10):1619-1625. PMID: 39209546
DOTATATE acetate purchased from MedChemExpress. Usage Cited in: J Nucl Med. 2024 Oct 1;65(10):1619-1625. [Abstract]
Total absorbed dose to cell nucleus for range of added activity concentrations of both 161Tb- and 177Lu-labeled DOTATATE (0-1.25 MBq/mL).
DOTATATE acetate purchased from MedChemExpress. Usage Cited in: J Nucl Med. 2024 Oct 1;65(10):1619-1625. [Abstract]
Radiolabeled DOTATATE (1 MBq/mL) resulted in a higher absorbed dose than did radiolabeled DOTA-LM3, because of DOTATATE's higher Bmax and higher internalization.
DOTATATE acetate purchased from MedChemExpress. Usage Cited in: J Nucl Med. 2024 Oct 1;65(10):1619-1625. [Abstract]
The nuclear dose-response data of both [177Lu]Lu- and [161Tb]Tb-DOTATATE (0-25 Gy) were best fitted with a linear model and could be fitted with a common, single curve.
DOTATATE acetate purchased from MedChemExpress. Usage Cited in: J Nucl Med. 2024 Oct 1;65(10):1619-1625. [Abstract]
The saturation binding assay represented total binding and nonspecific binding for different added activity concentrations of [161Tb]Tb-DOTATATE (0-60 nM) with a fixed molar activity of 100 MBq/nmol.
DOTATATE acetate purchased from MedChemExpress. Usage Cited in: J Nucl Med. 2024 Oct 1;65(10):1619-1625. [Abstract]
Clonogenic survival of CA20948 cells after treatment with [161Tb]Tb- and [177Lu]Lu-DOTATATE (0-1.5 MBq/mL) as a function of added activity concentration (MBq/mL).
-
-
-
Solvente y solubilidad
DMSO : 100 mg/mL (Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 8.33 mg/mL (ultrasonic and warming and heat to 60°C)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 11.11 mg/mL; Clear solution; Need ultrasonic and warming and heat to 60°C
Pureza y Documentación
-
Ficha de datos (283 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Jong M, et, al. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med. 2005 Jan;46 Suppl 1:13S-7S. [Content Brief]
[2]. Gains JE, et, al. 68Ga-DOTATATE and 123I-mIBG as imaging biomarkers of disease localisation in metastatic neuroblastoma: implications for molecular radiotherapy. Nucl Med Commun. 2020 Aug 10. [Content Brief]
[3]. Breeman WAP, et, al. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):917-20. [Content Brief]
[4]. Reubi JC, et, al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000 Mar;27(3):273-82. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
DOTATATE acetate Related Classifications
HY-106244A Related Classifications
Powered by Bioz